News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

05/19/2022 | Immatics

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab...
05/19/2022 | Noscendo GmbH

Software driven NGS-based diagnostics company Noscendo secures funding to revolutionize the diagnosis of infectious diseases

Noscendo, a leading provider of software-driven diagnostic solutions based on NGS (next-generation sequencing) that change the way infection-causing microbes are identifi...
04/28/2022 | CureVac AG

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone...
04/21/2022 | CureVac AG

CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study Demonstrated neutralizing capa...
04/08/2022 | Mireca Medicines GmbH

Mireca signs transformative deal with Nasdaq-listed Graybug Vision

Mireca’s proprietary cyclic guanosine monophosphate (cGMP) analogues to be developed using Graybug’s sustained-release drug delivery technologies The partnership is exclusive for the development of p...

Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron

Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concern The findings underscore the importance of new therapeutic appro...
03/23/2022 | Immatics

Immatics Announces Full Year 2021 Financial Results and Corporate Update

IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation Mul...
03/01/2022 | CureVac AG

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics CureVac RNA Printer GmbH to provide dedicated infrastruct...
02/16/2022 | Ovesco Endoscopy AG

HemoPill acute and HemoPill monitor are promising technologies for the detection of blood/hematin in the upper GI tract

Preliminary data of first clinical studies show fast and reliable detection of active bleeding in the upper GI tract and the small intestine by the HemoPill acute. Substa...
02/10/2022 | CureVac AG

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains Influenza candidate developed in collaboration ...
02/02/2022 | Ovesco Endoscopy AG

EMR+: Successful removal of a complex colonic lesion with help of the additional working channel AWC

A case report describes the successful removal of a 22 mm non-granular laterally spreading across-fold lesion in the proximal colon with the EMR+ technique ...
01/17/2022 | CureVac AG

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today ann...
01/13/2022 | Ovesco Endoscopy AG

OTSC: AGA Clinical Practice Update recommends OTSC and stentfix OTSC

The guideline recommends first-line OTSC therapy for esophageal perforation 1 – 2 cm in size, gastric perforations 1 – 3 cm in size, <13 mm type 1 duodenal perforations and certain colonic perforat...

Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

FDA Orphan Drug Designation (ODD) underscores strength of Atriva’s pipeline and high need for treatments for rare and neglected tropical diseases ODD allows Atriva to be...

Five years of Cyber Valley

AI research consortium celebrates anniversary December is a special month for Cyber Valley: five years ago, the research consortium was founded in the Stuttgart-Tübingen region. As an internationally renowned hotspot for artificial intelligence...
12/14/2021 | Immatics

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-p...

Regulating the "internal clock”

Newly identified sensor protein influences metabolism in cyanobacteria and day-night rhythm

Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva’s advisory board, bringing vast experience in late-stage pharmaceutical development Frans van Dalen, Pharm D., representative of Atri...
11/16/2021 | Immatics

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation p...